0QLN Stock Overview
Tecan Group AG provides laboratory instruments and solutions for pharmaceutical, biotechnology and in-vitro diagnostic companies, university research departments, and diagnostic and other laboratories.
Snowflake Score | |
---|---|
Valuation | 3/6 |
Future Growth | 2/6 |
Past Performance | 4/6 |
Financial Health | 5/6 |
Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for 0QLN from our risk checks.
Tecan Group AG Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | CHF322.60 |
52 Week High | CHF406.60 |
52 Week Low | CHF252.80 |
Beta | 0.60 |
1 Month Change | -13.38% |
3 Month Change | -1.16% |
1 Year Change | -20.21% |
3 Year Change | -27.60% |
5 Year Change | 40.87% |
Change since IPO | 214.73% |
Recent News & Updates
Recent updates
Shareholder Returns
0QLN | GB Life Sciences | GB Market | |
---|---|---|---|
7D | -4.6% | -8.6% | -0.9% |
1Y | -20.2% | -45.7% | -1.8% |
Return vs Industry: 0QLN exceeded the UK Life Sciences industry which returned -45.7% over the past year.
Return vs Market: 0QLN underperformed the UK Market which returned -1.8% over the past year.
Price Volatility
0QLN volatility | |
---|---|
0QLN Average Weekly Movement | 3.5% |
Life Sciences Industry Average Movement | 7.2% |
Market Average Movement | 4.8% |
10% most volatile stocks in GB Market | 11.3% |
10% least volatile stocks in GB Market | 2.6% |
Stable Share Price: 0QLN has not had significant price volatility in the past 3 months.
Volatility Over Time: 0QLN's weekly volatility (3%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1980 | 3,444 | Achim von Leoprechting | www.tecan.com |
Tecan Group AG provides laboratory instruments and solutions for pharmaceutical, biotechnology and in-vitro diagnostic companies, university research departments, and diagnostic and other laboratories. It operates through Life Sciences Business and Partnering Business segments. The company offers liquid handling and automation, microplate readers and washers, consumables, NGS reagents, immunoassays and antibodies, and software; and Tecan Labwerx, an automation solution.
Tecan Group AG Fundamentals Summary
0QLN fundamental statistics | |
---|---|
Market cap | CHF4.13b |
Earnings (TTM) | CHF132.08m |
Revenue (TTM) | CHF1.07b |
31.3x
P/E Ratio3.8x
P/S RatioIs 0QLN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
0QLN income statement (TTM) | |
---|---|
Revenue | CHF1.07b |
Cost of Revenue | CHF683.92m |
Gross Profit | CHF390.47m |
Other Expenses | CHF258.39m |
Earnings | CHF132.08m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
Aug 13, 2024
Earnings per share (EPS) | 10.31 |
Gross Margin | 36.34% |
Net Profit Margin | 12.29% |
Debt/Equity Ratio | 18.6% |
How did 0QLN perform over the long term?
See historical performance and comparison